Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 19Gastrointestinal 14Thoracic 6Lymphoid 5Sarcoma 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasms, Second Primary 1Neoplasms 1

Interventions

Radiotherapy 9Drug Therapy 9Cisplatin 9Gemcitabine 8Docetaxel 7Carboplatin 7Blood Specimen Collection 7Nivolumab 6Fluorouracil 6Pemetrexed 5Capecitabine 5pembrolizumab 4Surveys and Questionnaires 4Positron Emission Tomography Computed Tomography 4Paclitaxel 4Oxaliplatin 4Exercise 4Everolimus 4Data Collection 4Cetuximab 4indibulin 3icotinib 3Vincristine 3Trastuzumab 3Standard of Care 3Radiosurgery 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Thalidomide × Tumor-Agnostic × Clear all
NCT03777930 2018-12-19

The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

Shenzhen Fifth People's Hospital

Phase 4 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡